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Background: The aim of the present study was to evaluate the influence of tumor necrosis factor-alpha
(TNF-α) −308 G > A polymorphism on hepatocellular carcinoma (HCC) risk.
Methods: The present case? control study was conducted in a Han Chinese population consisting of 753 HCC patients
and 760 controls from May 2010 to March 2013. The −308 TNF-a promoter polymorphisms were detected. Conditional
logistic regression was performed to analyze the association between TNF-α −308 G > A polymorphism and the risk of
HCC, which were estimated by odds ratios (ORs) and their 95% confidence intervals (95% CIs).
Results: The genotypic frequencies in the cases were not similar to that of the controls, differences being statistically
significant (P = 0.002). Using the GG genotype as the reference genotype, AA was significantly associated with
increased risk of HCC (adjusted OR = 5.12, 95% CI = 2.31? 7.82). Similarly, AG + AA genotype showed 5.59-fold increased
HCC risk in a dominant model. Furthermore, we found A allele was significantly associated with increased risk of HCC,
compared with G allele (OR = 4.18, 95% CI = 1.76? 6.97).
Conclusion: The present study showed that TNF-α −308 G > A polymorphism was associated with increased HCC risk
in a Han Chinese population. Further prospective studies on large and different ethnic populations will be necessary to
confirm our findings and elucidate the underlying molecular mechanism for the development of HCC.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_199
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Hepatocellular carcinoma (HCC) is one of the common
malignant tumors globally, which is the fifth most preva-
lent cancer and the third cause of cancer-related deaths
worldwide [1]. Approximately 650,000 cases die from
HCC each year, and >75% of these cases occur in the
Asia-Pacific region [2]. It is indicated that China has a
very high incidence with about 55% of annual new cases
of HCC worldwide [3]. HCC has been one of the most
common causes of cancer-related deaths in China. Al-
though chronic hepatitis B virus (HBV) and hepatitis C* Correspondence: sd_zhangjunyong@126.com
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unless otherwise stated.virus (HCV) infections, aflatoxin B1, alcohol and nonal-
coholic steatohepatitis are regarded as the main carcino-
genic mechanism, only a few of these patients with these
risk factors develop HCC during their lifetime, suggest-
ing the etiology of HCC is not well clarified [4]. Thus
some genetic factors may contribute to the carcinogenic
mechanism.
Tumor necrosis factor-alpha (TNF-α) encodes a pro-
inflammatory cytokine that is secreted primarily by mac-
rophages and plays critical roles in the pathogenesis of
inflammatory autoimmune and malignant diseases. The
TNF-α protein induces the expression of adhesion mole-
cules, facilitating the invasion of metastatic tumor cells
[5], and high levels of endogenous TNF-α have been ob-
served in the blood of some cancer patients. Several
polymorphisms in the promoter region of TNF-α haveis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics of hepatocellular
carcinoma cases and healthy controls
Characteristics Cases (n) % Controls (n) % P-value
Number 753 49.8 760 50.2
Gender
Male 467 62.0 450 59.2 0.59
Female 286 38.0 310 40.8
Age (years)
<55 307 40.4 303 39.8 0.45
≥55 446 59.6 457 60.2
Alcohol drinking
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[6]. Of these, the TNF-α −308 G > A polymorphism is
the best studied. It involves the substitution of a guan-
ine (G) by an adenine (A) and is associated with an in-
crease in TNF-α expression levels [7]. TNF-α −308G >
A polymorphism has been reported to alter the risk of
several types of cancers, such as breast cancer, lung
cancer, non-Hodgkin lymphomas, and prostate cancer
[8-11]. However, the association between TNF-α −308 G >
A polymorphism and risk of HCC is controversial [12-15].
The present case? control study was performed to assess
the association of HCC risk and TNF-α −308 G >A poly-
morphism in a Han Chinese population.Yes 713 94.7 711 93.6 0.33
No 40 5.3 49 6.4
Tobacco smoking
Yes 719 95.5 701 92.2 0.31
No 34 4.5 59 7.8
HBsAg
+ 311 41.3 -
- 442 58.7 -
Anti-HCV
+ 241 32.0 -
- 512 68.0 -
Serum a-FP levels
<400 ng/ml 275 36.5 -
>400 ng/ml 478 63.5 -
Family history of HCC
Yes 119 15.8 -
No 634 84.2 -Methods
Study population
The present case ? control study consisted of 753 HCC
patients and 760 cancer-free controls from May 2010
to March 2013 at the Digestive Disease Department,
Shandong Provincial Hospital Affliated to Shandong
University. All subjects were unrelated Han Chinese liv-
ing in China. Health subjects were randomly selected
from health screening program participants to exclude
those with a history of cancer and other medical dis-
eases. All HCC patients were diagnosed on the basis of
histology or the combination of typical radiological
findings of HCC, and underwent surgery in Shandong
Provincial Hospital Affliated to Shandong University.
The tumor stage of HCC cases was evaluated on the
basis of the tumor-nodule-metastasis (TNM) classifica-
tion system. The HBsAg and anti-hepatitis C virus
(HCV) antibody were tested by microparticle enzyme
immunoassays using commercial assay kits, which were
used to determine the infection status of hepatitis B or
hepatitis C. Clinical characteristics data as well as re-
lated risk factors, including gender, age, smoking status,
drinking status, serum a-FP levels, family history of
HCC and HBV, HCV serological markers, were summa-
rized (Table 1).The present study was approved by the
Medical Ethics Committee of Shandong Provincial Hos-
pital Affliated to Shandong University, and informed
consent was obtained from all participants.DNA extraction
A 5 mL sample of venous blood was collected from
each subject into a test tube containing EDTA as anti-
coagulant. Genomic deoxyribonucleic acid (DNA) was
extracted from 2 mL of peripheral blood by the stand-
ard method with proteinase K digestion followed by
phenol ? chloroform extraction. After ethanol precipita-
tion, the DNA was dissolved in double distilled water
and frozen at −20?C until use.Polymorphism genotyping
The −308 TNF-a promoter polymorphisms were deter-
mined by method previously described [16]. Amplifica-
tion was performed in GeneAmp PCR System 9700
termocycler (Applied Biosystems, Singapore) with 100 ng
of genomic DNA, 25 pmol of each primer, 200 μM total
dNTP, 1.5 mM MgCI2, 1? PCR buffer and 2.5 U Taq
DNA polymerase (Promega, Madison, WI, USA). The fol-
lowing cycling conditions were used: 95?C for 5 min,
followed by 35 cycles of 94?C for 60 s, 58?C for 30 s and
72?C for 60 s, with a final extension at 72?C for 10 min.
Restriction enzyme digestion with NcoI (Promega,
Madison, WI, USA) of the PCR product was carried
out overnight and analyzed on a 3% agarose gel. DNA
products were visualized by ethidium bromide staining.
The -308G showed two fragments (homozygous for the
allele -308G), while its homologue -308A was un-
digested and resulted in a single band (homozygous for
allele -308A, lacking NcoI site). The presence of all
three fragments defined heterozygotic individuals.
Table 3 The association of TNF-α −308G > A
polymorphism with hepatocellular carcinoma risk









GG 611 733 1.00 (Reference)
AG 98 25 2.12 (1.25? 3.46) 0.02
AA 44 2 5.12 (2.31? 7.82) 0.003
Dominant genotype
GG 611 733 1.00 (Reference)
AG + AA 142 27 5.59 (2.41? 8.02) <0.001
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All statistical analyses were performed using the Statis-
tical Package for Social Science software version 18.0
(SPSS Inc., Chicago, IL, USA). Continuous variables
were reported as means ? standard deviation (SD), and
categorical variables were reported as frequencies (N)
and percentages (%). The χ2 test was used to assess dif-
ferences between cases and controls with regard to
clinical characteristics. A goodness-of-fit χ2 test was
used to evaluate the Hardy-Weinberg equilibriums in
controls. Conditional logistic regression was performed
to analyze the association between TNF-α −308 G > A
polymorphism and the risk of HCC, which were esti-
mated by odds ratios (ORs) and their 95% confidence
intervals (95% CIs). The significance levels of all tests
were set at P <0.05.
Results
Clinical characteristics of cases and controls
In the present case ? control study, a total of 1,513
Chinese Han subjects were enrolled, which consisting
of 753 HCC patients and 760 cancer-free controls. Table 1
showed the general characteristics of the studied subjects.
There were 467 males and 286 females in the HCC group,
and 450 males and 310 females in the control group. The
mean age of HCC patients was 53.3 years, and mean age
of cancer-free controls was 52.9 years. There were no sig-
nificant differences between HCC cases and cancer-free
controls with regarded to gender and age distribution. Be-
sides, for other general characteristics, such as alcohol
drinking, tobacco smoking, there were no significant dif-
ferences between HCC cases and cancer-free controls (all
P >0.05, shown in Table 1).
Genotypic frequencies of TNF-α −308 G > A in cases and
controls
The observed genotype distribution in the controls did
not differ from those expected from Hardy ? Weinberg
equilibrium (P > 0.05). Compared to healthy controls,
patients with HCC had lower frequency of GG genotype
(81.1% vs. 96.4%) and a higher frequency of AG (13.0%
vs. 3.2%). Homozygous AA genotype was found in 44
HCC patients and in 2 of controls. Thus, genotypic fre-
quencies in the cases were not similar to that of the con-
trols, differences being statistically significant (P = 0.002,
shown in Table 2).Table 2 Distribution of TNF-α −308 G > A genotypes in
cases and controls
TNF-α −308 G > A Cases % Controls % P value
GG 611 81.1 733 96.4 0.002
AG 98 13.0 25 3.2
AA 44 5.9 2 0.4The association of TNF-α −308G > A polymorphism with
HCC risk
We further analyzed the effects of the tested genotypes
under different genetic models (shown in Table 3). Using
the GG genotype as the reference genotype, AA was sig-
nificantly associated with increased risk of HCC (ad-
justed OR = 5.12, 95% CI = 2.31 ? 7.82). Similarly, AG +
AA genotype showed 5.59-fold increased HCC risk in a
dominant model. Furthermore, we found A allele was
significantly associated with increased risk of HCC, com-
pared with G allele (OR = 4.18, 95% CI = 1.76 ? 6.97).
Discussion
Advances in molecular and genetic epidemiology have
increased our knowledge of the mechanisms underlying
hepatocarcinogenesis and the relationships between sus-
ceptibility and individual genetic variations [17]. Based
on the genetic information, we determine the disease eti-
ology in terms of genetic determinants to be used for
identifying the high-risk individuals and perform target-
ing therapy to the individual ? s genetic make-up.
TNF-α is a member of the TNF/TNFR cytokine super-
family, and is an intercellular communicating molecule
involved in building transient or long-lasting multicellu-
lar structures [18]. It interacts with receptors TNFR1
and TNFR2, which participate in cellular signal trans-
duction pathways [19]. TNF-α plays an important role in
the regulation of cell differentiation, proliferation and
death as well as in inflammation and the innate and
adaptive immune response. It has also been implicated
in a wide variety of human diseases. The presence of
DNA sequence variations in the regulatory region mightRecessive genotype
AG + GG 709 758 1.00 (Reference)
AA 44 2 1.98 (0.95? 3.27) 0.06
Allele frequency
G 1,320 1,491 1.00 (Reference) 0.006
A 186 29 4.18 (1.76? 6.97)
1 Adjusted for sex, age, smoking status, and drinking status.
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the circulating level of TNF and thus increasing suscep-
tibility to human diseases, such as cancer. The TNF en-
hancer polymorphism has been implicated in several
diseases, and the TNF-a −308 polymorphism has been
described as the most important TNF polymorphism in
human disease susceptibility. The significance of these
polymorphisms reflects their possible influence on the
transcription of the TNF gene. TNF-α −308 G > A poly-
morphism involves the substitution of a guanine (G) by
an adenine (A) and is associated with an increase in TNF-
α expression levels [7]. TNF-α −308G > A polymorphism
has been reported to alter the risk of several types of can-
cers, such as breast cancer, lung cancer, non-Hodgkin
lymphomas, and prostate cancer [8-11]. For example, Jin
et al. found that the TNF- α −308G >A polymorphism
was not associated with breast cancer risk in the overall
population but that the A allele might be a protective fac-
tor for breast cancer in postmenopausal women, and the
AA genotype might be a breast cancer risk factor in pre-
menopausal women [8]. In Ma et al? study, a significantly
increased prostate cancer risk was found to be associated
with the TNF-α-308 G >A polymorphism (AA +AG vs.
GG: OR = 1.531, 95% CI = 1.093? 2.145; P = 0.013; AG vs.
GG: OR = 1.477, 95% CI = 1.047? 2.085; P = 0.026). Their
results suggested that the TNF-α-308 G > A poly-
morphism might significantly contribute to prostate
cancer susceptibility [11]. However, the association be-
tween TNF-α −308 G > A polymorphism and risk of
HCC is controversial [12-15]. The present case ? control
study was performed to assess the association of HCC
risk and TNF-α −308 G > A polymorphism in a Han
Chinese population. We found that the genotypic fre-
quencies in the cases were not similar to that of the
controls. We then analyzed the effects of the tested ge-
notypes under different genetic models. Using the GG
genotype as the reference genotype, AA was signifi-
cantly associated with increased risk of HCC. Similarly,
AG + AA genotype showed 5.59-fold increased HCC
risk in a dominant model. Furthermore, we found A al-
lele was significantly associated with increased risk of
HCC, compared with G allele. Our results were consist-
ent with the findings previously reported by Heneghan
et al. and Ho et al. [20,21], but different from Chen et
al ? s study [22].
Conclusions
In conclusion, the present study showed that TNF-α
−308 G > A polymorphism was associated with in-
creased HCC risk in a Han Chinese population. Fur-
ther prospective studies on large and different ethnic
populations will be necessary to confirm our findings
and elucidate the underlying molecular mechanism for
the development of HCC.Competing interests
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